🟢 Veradermics is trading 7% up in pre-market; no definitive catalyst identified

Veradermics is trading at $104.60 (+7.01%) in pre-market, while no definitive catalyst directly explaining the move has been identified.

• On September 3, 2026, Veradermics announced management will attend three September healthcare investor conferences.
• No earnings release, regulatory decision, financing announcement, or other definitive catalyst was identified.
• Broader markets are only modestly mixed ahead of the U.S. jobs report, so macro sentiment does not clearly account for the move.